The investigators asked whether ctDNA status could simultaneously identify patients with a lower probability of therapeutic benefit and a higher likelihood of developing immune-related toxicity. If confirmed, ctDNA could become an important tool not only for predicting efficacy but also for improving treatment selection and avoiding unnecessary exposure to checkpoint inhibitors.

Study Design

The investigators performed a post hoc biomarker analysis of the randomized phase III IMvigor010 trial.